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Purpose: The aim of this study was to clinically validate a multivariable normal tissue complication prob-
ability (NTCP) model for grade 2–4 swallowing dysfunction at 6 months after radiotherapy or chemora-
diation (SWALM6) in head and neck cancer patients treated with swallowing sparing intensity modulated
radiotherapy (SW-IMRT) and to test if SW-IMRT resulted in a reduction of the prevalence of SWALM6.
Materials and methods: The primary endpoint was SWALM6. For all 186 patients, a standard IMRT (parotid
sparing) and a SW-IMRT plan (additional constraints for swallowing organs at risk) was created. The
difference in NTCP for SWALM6 (DNTCPSWALM6 = NTCPstandard NTCPSW-IMRT) was calculated. Patients
were treated with SW-IMRT. The external validation of the NTCP model was analyzed by comparing
performance measures.
Results: The mean DNTCPSWALM6 was 4.9% (range 0.01–17.3%), with a significant lower mean predicted
NTCPSW-IMRT of 22.6% (95% CI 20.2–24.9%), compared to NTCPstandard of 27.5% (95% CI 24.9–29.9%)
(p < 0.001). There was a perfect correspondence of NTCPSW-IMRT with the observed prevalence of
SWALM6 (22.6%). The overall model performance, discrimination and ‘goodness of fit’ were good.
Conclusion: We externally validated the multivariable NTCP model for SWALM6 in SW-IMRT treated
patients, showing reduced swallowing dysfunction by reducing the dose parameters included in this
NTCP model.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 118 (2016) 298–303
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Swallowing dysfunction is one of the most devastating side
effects after definitive radiotherapy (RT) or chemoradiation (CHRT)
for head and neck cancer (HNC) and has a major impact on
health-related quality of life (HRQoL) [1–6].
Recently, we reported on the results of a large multicenter
prospective cohort study in which we developed multivariable
normal tissue complication probability (NTCP) models for swal-
lowing dysfunction [7]. In that study we identified two indepen-
dent risk factors for grade 2–4 swallowing dysfunction at
6 months after completion of treatment (SWALM6), including themean dose to the superior pharyngeal constrictor muscle (superior
PCM) and the mean dose to the supraglottic larynx, which is in line
with the results reported by other investigators [8–11]. We subse-
quently showed that swallowing sparing intensity modulated
radiotherapy (SW-IMRT) is expected to result in clinically relevant
reductions in the risk of swallowing dysfunction in approximately
half of the patients. SW-IMRT refers to IMRT with dose constraints
for both the parotid glands as well as for the swallowing organs at
risk (SWOARs), without compromising the dose to the planning
target volumes (PTV) and the parotid glands [12]. However, the
clinical validation of SW-IMRT remains to be determined.
Therefore, the purpose of this study was to clinically validate a
previously developed multivariable NTCP model for SWALM6 in a
cohort of patients treated with SW-IMRT and to investigate
whether SW-IMRT actually resulted in a reduction of the
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gland sparing IMRT).Methods and materials
Patients
The study population of this prospective cohort study was com-
posed of 186 consecutive patients treated from September 2010 to
September 2014 at the Department of Radiation Oncology of two
medical centers in The Netherlands: the VU University Medical
Center (VUMC), Amsterdam or the University Medical Center
Groningen (UMCG), Groningen. All patients were treated with
definitive RT for squamous cell HNC originating from the oral
cavity, pharynx or larynx, either alone or in combination with con-
comitant chemotherapy or cetuximab. All patients were subjected
to a standard follow-up program that included prospective
evaluation of acute and late toxicity, patient-rated symptoms and
HRQoL, prior to, during and at regular intervals after treatment
(NCT02435576, clinicaltrials.gov) [11,13].
Patients who previously underwent surgery, radiotherapy and/
or chemotherapy and those with prior malignancies, and/or distant
metastases were excluded. Patients with RTOG grade 2–4 swallow-
ing dysfunction at baseline were also excluded in order to ensure
that the observed swallowing dysfunction was induced by radia-
tion treatment itself and not by tumor extension. Furthermore
patients with residual disease or recurrence within 6 months were
excluded.Endpoints
The primary endpoint was defined as grade 2–4 swallowing
dysfunction according to the RTOG/EORTC Late Radiation
Morbidity Scoring Criteria, as assessed 6 months after completion
of treatment (SWALM6), which means that patients were not able
to eat solid food and were only able to eat semi-solid food, swallow
liquids or were dependent on tube feeding.Treatment
All organs at risk (OARs), including the salivary glands, and the
SWOARs were delineated as previously described [14,15]. Regions
of interest, IMRT planning and optimization for SW-IMRT were
described previously in detail [12].Study design and statistical analysis
The validation of SW-IMRT was performed according to the
model-based approach [16]. Model-based validation means that
multivariable NTCP models developed in a population with a
certain radiation technique (in this case standard IMRT and
three-dimensional conformal RT (3D-CRT)) are also valid in an
independent subsequent population treated with another radiation
technique (in this case SW-IMRT) (external validation). This implies
that dose reductions (DDose) obtained with the new technology
result inNTCP reductions (DNTCP) as predicted by themultivariable
NTCP model and thus that the new technique indeed contributes to
less toxicity. For this purpose, the following steps were made:
Step 1 (NTCPstandard): For all patients, a standard IMRT treatment
plan was created, using dose constraints for the parotid glands but
without dose constraints for the SWOARs. For this plan, the NTCP
value for SWALM6 (NTCPstandard) was calculated using the equation
of the prediction model for SWALM6 as described by Christianen
et al. [7]:NTCP = (1 + eS)1, in which S = 6.09 + (mean dose superior
PCM ⁄ 0.057) + (mean dose supraglottic larynx ⁄ 0.037).
This plan was then saved and stored.
Step 2 (NTCPSW-IMRT): This standard IMRT plan was then further
optimized into a SW-IMRT plan with similar planning objectives
for the parotid glands and target volumes, but with additional con-
straints for the SWOARs. During the planning procedures, attempts
were made to reduce the dose to the SWOARs as much as possible
in an iterative process, until the dose to other organs at risk started
to rise (parotid glands, oral cavity or spinal cord) and/or the dose
levels to the PTV’s were compromised. For this plan, the NTCP
value for SWALM6 (NTCPSW-IMRT) was calculated with the same
equation that was used in step 1.
Subsequently, DNTCPSWALM6 was calculated, defined as
NTCPstandard  NTCPSW-IMRT, and thus corresponding with the pre-
dicted NTCP reduction that could be obtained with SW-IMRT as
compared to standard IMRT in each individual patient. Patients
were divided into 2 groups, including a LOW DNTCPSWALM6 group
if DNTCPSWALM6 was 0–5% and a HIGH DNTCPSWALM6 group if
DNTCPSWALM6 was more than 5%. This threshold was chosen in
advance on an arbitrary basis.
Step 3 (actual treatment): Patients were then actually treated
with SW-IMRT and prospectively followed using exactly the same
data registration program as used in the previous population trea-
ted with 3D-CRT or standard IMRT in which the multivariable
model was developed [7].
Step 4 (external model validation): The external validation of the
NTCP model was done by a number of performance measures of
the NTCP model in the SW-IMRT cohort to that obtained in the
original cohort treated with standard IMRT or 3D-CRT that
was used to develop the model [7]. For this purpose, we used
Monte–Carlo simulations using repeated random drawings of the
outcomes according to the model NTCP to generate the expected
distributions of the performance measures, based on the model
and the case-mix of the cohort, and calculated single sided
p-values (i.e., testing the null-hypothesis that the actual performance
was not worse than expected). Overall model performance was
described with the explained variance (using the Nagelkerkes R2)
and the scaled Brier score. The Brier score is the average squared
difference between the predicted probability and the actual out-
come. The scaled Brier score is a recalculated Brier score that will
give a more robust comparability of the accuracy of the model. A
scaled Brier score should be as close to 1 as possible (a perfect
model), and is 0 for a non-informative model [17,18]. For the dis-
crimination ability of the model, we calculated the area under
the receiver operating characteristic curve (AUC), and the discrim-
ination slope, defined as the absolute difference between the mean
predicted NTCP value for patients with and without the outcome
[17,18]. Finally, a Hosmer–Lemeshow goodness-of-fit test was per-
formed to evaluate the calibration of the model. Model calibration
describes to what extent the observed prevalence in a number of
equally-sized subgroups corresponds with the expected values
based on the average NTCP-value of each subgroup. The model’s
predictions fit the data at an acceptable level if the Hosmer–
Lemeshow goodness-of-fit test statistic is >0.05 [19]. Since in the
previous cohort [7] we only assessed model performance using
the AUC, we retrospectively performed all the above mentioned
model performance measures in the previous cohort as well.
Step 5 (technique validation): To evaluate the ability of SW-IMRT
to reduce the prevalence of SWALM6, we analyzed if the observed
prevalence of SWALM6 significantly differed from the average
predicted NTCPstandard, using a non-parametric two-sided test.
Data were analyzed using SPSS Statistics for Windows,
version 19.
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The study population of this prospective cohort study was com-
posed of 186 patients with a mean age of 64 years. The majority of
patients were males (74%). The pre-treatment characteristics of the
patients are listed in Table 1.
The mean dose in all SWOARs and the contralateral parotid
glands was significantly lower with the SW-IMRT plans compared
to the standard IMRT plans, whereas the mean dose in the ipsilat-
eral parotid and submandibular glands remained the same
(Table 2A).
The DNTCPSWALM6 varied widely between individual patients,
with a mean DNTCPSWALM6 of 4.9% (range 0.01–17.3%). Out of
186 patients, 87 (47%) were classified as having HIGH
DNTCPSWALM6 while 99 patients (53%) were classified as having
LOW DNTCPSWALM6 (Fig. 1). The LOW and HIGH DNTCPSWALM6
groups differed significantly with regard to a number of pretreat-
ment variables (Table 1). The patients in the HIGH DNTCPSWALM6
group had higher T-stages, had more primary tumors originating
from nasopharynx and oropharynx, and were more often treated
with CHRT or conventional RT (Table 1). Moreover, the doses
delivered to some of the SWOARs were significantly higher
(Table 2B and C).
In the standard IMRT and 3D-CRT patient cohort used for model
development [7], the overall model performance was good with a
scaled Brier of 0.23 (95% CI 0.15–0.31) and an explained variance
(R2) of 0.31 (95% CI 0.21–0.41). Discrimination in terms of the
AUC was 0.80 (95% CI 0.75–0.86) with a discrimination slope of
0.22 (95% CI 0.18–0.25). The Hosmer–Lemeshow ‘‘goodness of fit”
had a p-value of 0.19, indicating a good agreement between
expected and observed rates.
Similar results were seen in the validation of the current
SW-IMRT patient cohort. The overall model performance had an
actual scaled Brier of 0.13 (95% CI 0.03–0.22, with p = 0.36 for a
single sided test with respect to the expected distribution based
on the model and the case-mix, such that we cannot reject the
null-hypothesis that the performance is not worse than expected)
and an actual explained variance (R2) of 0.21 (95% CI 0.08–0.33,
p = 0.34). The discrimination ability of the model showed an
actual AUC of 0.75 (95% CI 0.68–0.82, p = 0.32) and an actualTable 1
Patients characteristics.
Characteristics All patients
(n = 186)
Number
Sex Male 138
Female 48
Age, years 18–65 109
>65 77
Tumor classification T1–T2 103
T3–T4 83
Node classification N0 96
N+ 90
Primary Site Larynx 85
Oropharynx 64
Oral cavity 8
Hypopharynx 21
Nasopharynx 8
Treatment modalities Conventional radiotherapy 51
Accelerated radiotherapy 63
Chemoradiation 61
Bioradiation 11
* P-value LOW NTCP reduction versus HIGH NTCP reduction, based on chi-square.discrimination slope with a value of 0.14 (95% CI 0.10–0.18,
p = 0.30). The Hosmer–Lemeshow ‘‘goodness of fit” had a p = 0.74,
indicating a good agreement between expected and observed rates.
Fig. 2 shows the calibration plots of both cohorts.
The mean predicted NTCPSW-IMRT in all 186 patients was 22.6%
(95% CI 20.2–24.9%), which was significantly lower than the mean
predicted NTCPstandard which was 27.5% (95% CI 24.9–29.9%)
(p < 0.001). The observed prevalence of SWALM6 was 22.6%, which
corresponded perfectly with the mean predicted NTCPSW-IMRT
values (Fig. 3).
In the LOW DNTCPSWALM6 group, the mean predicted
NTCPstandard and mean predicted NTCPSW-IMRT was 23.3% (95% CI
19.2–27.6%) and 21.3% (95% CI 17.4–25.4%), respectively
(p < 0.001). In the LOW DNTCPSWALM6 the observed prevalence
was 20.2% which corresponded with both 95%-confidence intervals
of the mean predicted NTCPstandard and NTCPSW-MRT (Fig. 3).
In the HIGH DNTCPSWALM6 group, the mean predicted
NTCPstandard was 32.2% (95% CI 30.2–34.3%) while the mean
predicted NTCPSW-IMRT was significantly lower, i.e. 24.1% (95% CI
22.1–26.3%) (p < 0.001). The observed prevalence of SWALM6 in
the HIGH DNTCPSWALM6 was 25.3% and was within the mean
predicted NTCPSW-IMRT 95%-confidence interval (Fig. 3).
Discussion
This study is the first to report the clinical validation of
SW-IMRT using a model-based approach. Our results show that
by adding dose constraints for SWOARs during treatment planning
optimization a clinically relevant DNTCP can be obtained in
approximately 50% of the patients and that subsequent lower
prevalences of SWALM6 are observed if the dose to the superior
PCM and the supraglottic larynx can indeed be sufficiently
decreased. In this regard, it should be noted that we arbitrarily
defined a DNTCP-threshold of 5% as clinically relevant.
In the current study population, we were able to significantly
reduce the dose to the superior PCM and supraglottic larynx result-
ing in a significant average NTCP reduction from 27.5% obtained
with standard IMRT to 22.6% as obtained with SW-IMRT. The
expected average NTCPSW-IMRT corresponded perfectly with the
observed prevalence of 22.6%. These results are in line with thoseLOW NTCP
reduction group
(DNTCP: 0–5%)
(n = 99)
HIGH NTCP
reduction group
(DNTCP >5%)
(n = 87)
P-value*
% Number % Number %
74 77 78 61 70 .233
26 22 22 26 30
59 55 56 54 62 .368
41 44 44 33 38
55 63 64 40 46 .016
45 36 36 47 54
52 57 58 39 45 .083
48 42 42 48 55
46 50 51 35 40 .007
35 27 27 37 43
4 5 5 3 3
11 16 16 5 6
4 1 1 7 8
27 24 24 27 31 .006
34 42 43 21 24
33 24 24 37 43
6 9 9 2 2
Table 2
Dose distribution parameters.
Dose (Gy) according to
actually given SW-IMRT plan
Dose (Gy) according to BACK
UP standard IMRT plan
Difference between SW-IMRT
and standard IMRT (Gy)
P-value*
Average Dmean 95% CI Average Dmean 95% CI
(A) All patients
Organ at risk
Superior pharyngeal constrictor muscle 41.5 38.2–44.7 44.4 41.0–47.7 2.9 <.001
Middle pharyngeal constrictor muscle 46.8 43.9–49.7 50.9 48.2–53.5 4.1 <.001
Inferior pharyngeal constrictor muscle 53.7 51.4–55.7 57.4 55.4–59.2 3.7 <.001
Cricopharyngeal muscle 49.2 47.1–51.2 52.2 50.2–54.0 3.0 <.001
Esophageal inlet muscle 35.4 33.0–37.5 41.7 39.2–43.7 6.3 <.001
Supraglottic larynx 54.3 52.0–56.3 58.1 56.1–59.8 3.8 <.001
Glottic larynx 56.6 54.0–58.9 58.9 56.7–61.0 2.3 <.001
Parotid gland ipsilateral 27.8 25.4–30.4 27.9 25.6–30.4 0.1 .120
Parotid gland contralateral 20.9 19.1–22.7 21.5 19.7–23.3 0.6 <.001
Submandibular gland ipsilateral 49.6 46.0–53.1 49.8 46.2–53.2 0.2 .044
Submandibular gland contralateral 44.0 40.5–47.2 44.3 40.8–47.5 0.3 .003
(B) LOW NTCP reduction group (DNTCP: 0–5%)
Structure
Superior pharyngeal constrictor muscle 34.3 29.0–39.4 35.6 30.3–40.8 1.3 <.001
Middle pharyngeal constrictor muscle 41.0 36.2–45.8 44.6 40.1–49.1 3.6 <.001
Inferior pharyngeal constrictor muscle 54.9 51.5–57.9 57.4 54.3–60.4 2.5 <.001
Cricopharyngeal muscle 48.7 45.6–51.8 51.0 48.0–54.0 2.3 <.001
Esophageal inlet muscle 30.7 27.1–34.1 36.0 32.4–39.2 5.3 <.001
Supraglottic larynx 54.2 50.4–57.1 56.8 53.2–59.7 2.6 <.001
Glottic larynx 59.1 55.6–62.4 60.1 56.7–63.1 1.0 <.001
Parotid gland ipsilateral 21.9 18.4–25.3 21.8 18.4–25.2 0.1 .591
Parotid gland contralateral 16.5 13.7–19.2 16.8 14.0–19.5 0.3 .006
Submandibular gland ipsilateral 39.9 34.1–45.5 40.3 34.5–45.7 0.4 .002
Submandibular gland contralateral 34.7 29.2–39.6 35.0 29.5–39.9 0.3 .008
(C) HIGH NTCP reduction group (DNTCP >5%)
Structure
Superior pharyngeal constrictor muscle 49.7 46.9–52.5 54.4 52.3–56.6 4.7 <.001
Middle pharyngeal constrictor muscle 53.6 51.7–55.8 58.2 56.7–59.8 4.6 <.001
Inferior pharyngeal constrictor muscle 52.4 49.8–55.5 57.4 55.4–59.6 5.0 <.001
Cricopharyngeal muscle 49.8 47.5–52.4 53.5 51.6–55.5 3.7 <.001
Esophageal inlet muscle 40.7 38.4–43.0 48.2 46.6–49.9 7.5 <.001
Supraglottic larynx 54.4 51.9–56.8 59.4 57.6–61.2 5.0 <.001
Glottic larynx 53.7 50.8–57.2 57.6 55.3–60.3 3.9 <.001
Parotid gland ipsilateral 34.5 32.0–37.1 34.9 32.5–37.3 0.4 .002
Parotid gland contralateral 26.0 24.3–27.8 27.0 25.2–28.8 1.0 <.001
Submandibular gland ipsilateral 60.9 59.1–62.5 60.8 59.1–62.4 0.1 .628
Submandibular gland contralateral 54.8 52.6–56.6 54.9 52.9–56.7 0.1 .165
y P-value LOW NTCP reduction versus HIGH NTCP reduction, based on independent sample t-test.
* P-value actually given dose SW-IMRT versus BACK UP standard IMRT, based on paired sample t-test.
Model development cohort (standard IMRT) Current study cohort (SW-IMRT)
Fig. 1. NTCP comparison plot. The plot shows the NTCP values for SW-IMRT as a function of the NTCP values for standard IMRT. All dots are below the black dashed line
indicating that the NTCP values for SW-IMRT are generally lower than those obtained with standard IMRT. The blue squares indicate patients withPDNTCP >5% and the red
dots indicate patients with DNTCP 0–5%. Abbreviations: IMRT = intensity modulated radiotherapy, SW-IMRT = swallowing sparing IMRT, NTCP = normal tissue complication
probability.
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Fig. 3. Observed prevalence after SW-IMRT (dark blue) compared to predicted
NTCP values for SW-IMRT (light blue) and to predicted NTCP values for standard
IMRT based on the back up standard IMRT plans (orange). The observed prevalences
in all patients and in those in the HIGH DNTCP groups corresponded significantly
better with the average NTCP values for SW-IMRT than with those for standard
IMRT (red arrow). Abbreviations: IMRT = intensity modulated radiotherapy, SW-
IMRT = swallowing sparing IMRT, NTCP = normal tissue complication probability.
302 Validation of swallowing sparing IMRTreported by Feng et al. who observed low rates of dysphagia at
1 year after chemoradiation after IMRT with sparing of the pharyn-
geal constrictors and glottic regions [20,21].
It should be noted that in this study, we only included patients
with primary tumors originating from the oral cavity, nasophar-
ynx, oropharynx, hypopharynx and larynx, while in our previous
cohort [7] also other primary tumor sites were included. When
confining the analysis to similar tumor sites as used in the current
study, the prevalence of SWALM6 in patients treated with standard
IMRT in our previous study was 27.9%, which corresponded nicely
with the mean predicted NTCPstandard found in the current study
(27.5%), indicating that the expected prevalence of SWALM6 wouldhave been similar to that observed in the previous cohort when
treated with standard IMRT.
The NTCP for SWALM6 with standard IMRT and the
DNTCPSWALM6 varied widely between individual patients. We
found differences between the pretreatment variables of the
patients in the LOW (0–5%) and HIGH (>5%) DNTCPSWALM6 groups.
The HIGH DNTCPSWALM6 group, consisted of patients with more
advanced T-stages, and with more nasopharyngeal and oropharyn-
geal cancers, which corresponds with the higher doses
administered to the most important SWOARs, i.e. the superior
PCM and supraglottic larynx. Consequently, patients in the HIGH
DNTCPSWALM6 group more often received CHRT or conventional RT.
As shown in a previous report on the implementation of
SW-IMRT [22], DNTCP obtained with SW-IMRT depend on uni-
versus bilateral neck RT, tumor location and the amount of overlap
SWOAR-PTV. Also in the current study, we experienced several rea-
sons why DNTCPSWALM6 remained low in some of the patients. In
the first place, the SWOARs sometimes partly or even completely
overlapped with the PTV, and therefore little to no reduction in
the SWOARs could be obtained without compromising the dose
to the PTV. Secondly, lowering the dose to the SWOARs in some
cases led to an increase in the dose to other OARs which was not
allowed according to predefined criteria. Finally, for a small sub-
group of patients the initial NTCP was already low and could not
be reduced any further.
Recently, Vainshtein et al. reported on favorable long-term
patient-reported outcome of swallowing complaints among
HPV-positive oropharyngeal cancer patients treated with chemora-
diation with IMRT with dose constraints for both salivary glands
and a number of swallowing structures, which further support
the validity of IMRT aimed at the reduction of dysphagia [23].
The relationship between dose–volume parameters and swallow-
ing dysfunction after RT or CHRT, and on the potential benefit of
sparing SWOARs with IMRT, but the clinical relevance of these
reductions remained to be determined [2,21–26]. Some of the
other investigators who previously reported on the potential
dosimetric benefits of SW-IMRT, accepted reduced coverage of
the (elective) PTV (i.e. by using split field IMRT) [22,26,27–30],
which makes it difficult to compare these results with those from
the current study.
In the current study we used the previously described model-
based approach to validate SW-IMRT. The model-based approach
is a stepwise methodology, that has been developed to effectively
select patients that are expected to benefit most from new radia-
tion delivery techniques aiming at the reduction of radiation-
induced side effects, such as proton therapy [16]. However, this
method is also applicable for the development and validation of
other radiation delivery techniques, such as SW-IMRT.
At present, randomized trials are still considered gold standard
in evidence-based medicine. This is certainly true for new inter-
ventions aiming at improving treatment efficacy in terms of local
control and survival. However, evidence based medicine is not
restricted to randomized trials and meta-analyses. It involves
tracking down the best external evidence with which to answer
our clinical questions [31]. For new radiation techniques that are
only aiming at reducing side effects without changing the strategy
with regard to tumor control (i.e. target volumes and fractiona-
tion), the model-based approach can be considered as a good alter-
native for an RCT.
The model-based approach consists of two phases (phase a): a
phase aiming at the development of a new radiation technique (3
steps), and a consecutive phase (phase b) including a prospective
observational cohort study aiming at the clinical validation of the
new radiation delivery technique (step 4). For swallowing dysfunc-
tion and SW-IMRT, phase a, including multivariable NTCP model
development followed by in silico planning comparisons have been
M.E.M.C. Christianen et al. / Radiotherapy and Oncology 118 (2016) 298–303 303reported in our previously published papers [7,12]. In the current
paper we reported on phase b. The multivariable NTCP model for
SWALM6 showed a significant relationship between the dose to
the superior PCM and supraglottic larynx and SWALM6. However,
such relationship does not strictly guarantee a causal relationship
between these two dose parameters and SWALM6. Therefore, an
essential step in assessing the generalizability and causality of
the multivariable NTCP model for SWALM6 was external validation
in an independent patient cohort treated with a radiation
technique in which the relevant dose parameters were further
optimized [32]. The current study showed that the multivariable
NTCP model for SWALM6 still performed well in this independent
patient cohort with a modified IMRT technique and that the
predictions based on the actual treatment technique (SW-IMRT)
corresponded very well with the observed prevalence.”
In conclusion, we externally validated the multivariable NTCP
model for SWALM6 in a subsequent independent cohort of patients
treated with SW-IMRT and showed that by reducing the dose
parameters included in this NTCP model, the risk of swallowing
dysfunction can be reduced.
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